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Preferential differences in vaccination
decision-making for oneself or one’s child
in The Netherlands: a discrete choice
experiment
Joram Hoogink1,2* , Frederik Verelst3, Roselinde Kessels4, Albert Jan van Hoek1,5, Aura Timen1,6, Lander Willem3,
Philippe Beutels3, Jacco Wallinga1,2 and G. Ardine de Wit7,8*
Abstract
Background: To optimize the focus of future public information campaigns in The Netherlands promoting the
uptake of vaccines among adults and children, we quantified the contribution of several attributes to the
vaccination decision.
Method: We performed a discrete choice experiment (DCE) among Dutch adults including six attributes, i.e.
vaccine effectiveness, vaccine-preventable burden of disease (specified in severity and frequency), accessibility of
vaccination in terms of co-payment and prescription requirements, frequency of mild side-effects, population-level
vaccination coverage and local vaccination coverage among family and friends. Participants answered the DCE from
their own perspective (‘oneself’ group) or with regard to a vaccine decision for their youngest child (‘child’ group).
The data was analysed by means of panel mixed logit models.
Results: We included 1547 adult participants (825 ‘oneself’ and 722 ‘child’). Vaccine effectiveness was the most
important attribute in the ‘oneself’ group, followed by burden of disease (relative importance (RI) 78%) and
accessibility (RI 76%). In the ‘child’ group, burden of disease was most important, but tied closely with vaccine
effectiveness (RI 97%). Of less importance was the risk of mild vaccine-related side-effects and both population and
local vaccination coverage. Interestingly, participants were more willing to vaccinate when uptake among the
population or family and friends was high, indicating that social influence and social norms plays a role.
Conclusions: Vaccine effectiveness and disease severity are key attributes in vaccination decision-making for adults
making a decision for themselves and for parents who decide for their children. Hence, public information
campaigns for both adult and child vaccination should primarily focus on these two attributes. In addition,
reinforcing social norms may be considered.
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Background
Vaccination is one of the major contributors to the glo-
bal improvement of health and life expectancy [1, 2].
The success of vaccination programmes is dependent on
a high uptake, which is currently threatened globally by
an increase in vaccine hesitancy and refusal [3–6]. Since
2012, a decline in vaccine uptake has also been observed
in The Netherlands, a country with high uptake rates
historically [7]. To counter this decline, it is crucial to
understand the importance of individual determinants of
vaccine decision-making.
Determinants of vaccine decision-making have been
studied thoroughly over the past years, revealing factors
like (perceived) vaccine safety, risk perception, (perceived)
vaccine effectiveness, and social norms and beliefs (for ex-
ample religious or anthroposophical) [6, 8–11]. Multiple
factors account for the recent decline in vaccine uptake,
but two of the main drivers are lower vaccine confidence
and risk perception, the latter referring to the perceived
severity and susceptibility of vaccine-preventable diseases.
Vaccine confidence is associated with the belief in vaccine
effectiveness and safety [9, 12]. Risk perception is affected
by the successes of vaccination programmes in the past,
which have markedly decreased the incidence of many
vaccine-preventable diseases. In this situation, individuals
may increasingly become complacent to the threat and
burden of these infectious diseases [13–15]. Closely linked
to the concepts of risk perception and vaccine confidence
is “freeriding” behaviour, i.e. relying on the vaccination of
others and the effect of herd immunity to protect oneself
[16], implying that high coverage leads to rational refusal
of vaccination. This purely rational behaviour has been
observed within experimental settings, where participants
played so-called vaccination games [17]; however multiple
observational studies have found evidence against this
assumption [18, 19].
The Dutch vaccination programme consists of vacci-
nations that target different age and risk groups, includ-
ing children, adolescents, pregnant women, clinical risk
groups and elderly. It is likely that these different groups
have a different inclination towards vaccination, based
on different perspectives on individual risk and expecta-
tions with regard to future health. For example, an adult
member of a risk group may have entirely different con-
siderations than an adolescent, or a parent who has to
make the decision about vaccinating a young child.
Discrete choice experiments (DCE) have been used to
study vaccine decision-making, both in The Netherlands
and elsewhere [20–22]. These studies focussed either on
adults taking decisions for themselves or on parents de-
ciding for their children. None of these studies used the
same DCE for both groups, hindering a direct compari-
son of preferences. Therefore, we have used a similar
experimental design enabling a comparative study of
vaccine decision-making between these two groups in
The Netherlands.
Methods
We employed a recently developed DCE design that was
used in a study about vaccine decision-making in Flanders
and South Africa [23, 24]. This choice design presented
respondents with 10 choice sets of two hypothetical pro-
files of an unknown (general) vaccine against an unknown
disease. For each choice set, respondents had to indicate
their preferred vaccine profile. Besides respondents’ an-
swers to the choice tasks, we gathered information on
socio-economic factors as well as health literacy, in order
to be able to explore the results for different groups. The
survey was conducted in June–July 2018 among Dutch
speaking adults in The Netherlands who are part of an on-
line (registered) consumer panel. Recruitment of partici-
pants followed pre-defined sample quotas regarding
background characteristics (Table 1). Sample quotas for
gender and age were defined based on national statistics
[25]. Generally, orthodox Protestants have a lower vaccine
uptake due to religious beliefs [26–28]. To be able to cap-
ture their preferences, at least 10% of the respondents
came from municipalities where more than 5% of the in-
habitants voted for the orthodox Protestant political party
(SGP) during the 2017 national elections [29]. Finally, for
the purpose of being able to compare the decision with re-
gard to a child to the decision for oneself we used a prede-
fined sample quota of 50% inclusion of parents of at least
one child below 18. Only one respondent per household
could participate.
We divided study participants in two groups, referred to
as the ‘oneself’ and ‘child’ group. Respondents without
children under 18 years of age could only be allocated to
the ‘oneself’ group, remaining respondents were randomly
allocated to either the ‘oneself’ or ‘child’ group. The ‘one-
self’ group answered questions on vaccinating themselves,
the ‘child’ group on vaccinating their youngest child. As
an incentive for participation, respondents received credit
rewards, transferable into coupons or air miles.
The questionnaire consisted of five parts involving (1)
background characteristics of the respondent; (2) vac-
cine-related attitudes; (3) the DCE; (4) risk perception of
infectious diseases and (5) health literacy. The full ques-
tionnaire is available in the Additional Material 1.
Background characteristics included: gender; age; 4-digit
postal code; level of education; household composition;
family size (number of children); age of youngest child;
mother's country of birth; professional experience in the
healthcare sector; previous exposure to severe diseases;
eligibility for influenza vaccination (i.e. belonging to a risk
group that qualifies for annual vaccination via the GP);
past acceptance of influenza vaccination (if eligible);
smoking status; beliefs that influence (attitude towards)
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vaccination decisions; religious background; and past ac-
ceptance of National Immunization Programme (NIP)
vaccination for one’s children (if any).
The second part, surveying vaccine-related attitudes,
contained 21 statements, each focussed on a particular
aspect of the vaccination programme. These
Table 1 Comparison of sample characteristics with pre-defined sample quota and population statistics
Characteristic Adult group
N = 825 (%)
Child group
N = 722 (%)
Sample
N = 1547 (%)
Dutch population (%)a Predefined quota
N = 1500 (%)
Gender
Male 55.0 40.0 48.0 49.0 49.0
Female 45.0 60.0 52.0 51.0 51.0
Age group
18–34 22.8 32.4 27.3 26.0 26.0
35–49 14.2 50.7 31.2 28.6 28.6
50–65 32.7 16.2 25.0 26.6 26.6
66–85 30.3 0.7 16.5 18.8 18.8
Educational level
Low 21.9 12.9 17.7 31.4
Medium 44.8 46.0 45.4 38.2 NA
High 33.2 41.1 36.9 28.9
Province
Drenthe 2.3 2.9 2.6 2.9
Flevoland 1.7 1.7 1.7 2.4
Friesland 4 4.4 4.2 3.8
Gelderland 12.1 9.4 10.9 12.0
Groningen 3.5 5.5 4.5 3.4
Limburg 6.9 6.5 6.7 6.5
Noord-Brabant 16.8 14.0 15.5 14.7 NA
Noord-Holland 13.8 17.9 15.7 16.5
Overijssel 6.3 7.6 6.9 6.7
Utrecht 7.5 6.6 6.9 7.5
Zeeland 2.7 1.9 2.3 2.2
Zuid-Holland 21.2 20.1 20.7 21.4
Missing 1.1 1.4 1.2
Biblebelt 17.1 9.8 13.7 3.0 10.0
Cultural background
Dutch 90.4 88.2 89.4
Western European 3.8 3.6 3.7 NA
Other 5.8 8.2 6.9
Household
Living alone 23.6 –
12.6
Living alone with children 3.8 16.9 9.9
Living together without children 40.8 –
21.8
NA
Living together with children 23.9 83.1 51.5
Other 7.9 –
4.2
Health literacy (SBSQ) > 2 91.1 90.7 90.9 NA NA
aSource: Statistics Netherlands
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statements were adopted from a selection of previ-
ously conducted questionnaires on vaccine decision
behaviour of parents as well as elderly [12, 22, 30]. All
statements had to be answered on a 5-point Likert
scale (mostly ranging from strongly disagree to
strongly agree).
The third part, the DCE, assigned each respondent to
10 choice sets of two unlabelled vaccine profiles. To cap-
ture all main and interaction effects, we created a design
of 50 choice sets, divided into five subsets of 10 choice
sets, using a Bayesian D-optimal design [31]. The subsets
were distributed randomly and evenly among the partici-
pants in both the ‘oneself’ and ‘child’ group. Each choice
task was composed of six attributes, but only the levels
of three of them differed between the two alternatives.
These differences were made explicit by marking them
in yellow. Respondents were, however, asked to take the
levels of all attributes into account [31–34]. The attri-
butes included were vaccine effectiveness, burden of dis-
ease for which the vaccine protects, vaccine-related side-
effects (VRSE), accessibility of vaccination; population
coverage and local coverage. Attributes were selected
based on literature on DCEs in the context of vaccin-
ation [18–20, 35–38] and health economics in general
[18–20, 32, 35–40], as well as qualitative studies. A focus
group study (n = 16), pilot study (n = 41) and a soft
launch with free-form feed-back (n = 184) in the original
Flemish target population resulted in the final selection
and finetuning of the six attributes. Attributes as burden
of disease, vaccine effectiveness, VRSE and accessibility
are utilized frequently in DCE studies in the field of vac-
cination. Vaccine coverage, both at the population and
the local level, is included less often in vaccine DCEs, al-
though its importance is well described in literature
about behavioural change models [41]. For the full de-
scription of the survey design, we refer the interested
reader to [24]. The attributes and levels of the DCE are
shown in Table 2.
The fourth part of the questionnaire assessed the par-
ticipants’ perception of the relative severity of and sus-
ceptibility of themselves or their child for measles,
influenza, a urinary tract infection and leukaemia [42].
Also, respondents had to indicate from which sources
they received information or whom they would consult
regarding vaccination decisions.
Finally, the respondents’ health literacy was assessed
using Chew’s Set of Brief Screening Questions (SBSQ),
which is a validated subjective measure of health literacy
containing three items: ‘How confident are you filling
out forms by yourself?’ (Confident with Forms), ‘How
often do you have someone (like a family member,
friend, hospital/clinic worker or caregiver) help you read
hospital materials?’ (Help Read), and ‘How often do you
have problems learning about your medical condition
because of difficulty understanding written information?’
(Problems Reading) [43–45]. Responses were scored on
a 5-point Likert scale ranging from 0 (always or not cer-
tain at all) to 4 (never or completely certain). A total
Table 2 DCE attributes and levels
Attribute Level description
1. Vaccine effectiveness a) Protects 50% of vaccinated individuals
b) Protects 90% of vaccinated individuals
2. Burden of disease a) The disease, against which the vaccine protects is rare and often mild: hospitalization is exceptional and the
disease is not life-threatening
b) The disease, against which the vaccine protects is rare and often severe: often with hospitalization and the
disease is life-threatening
c) The disease, against which the vaccine protects is common and often mild: hospitalization is exceptional and
the disease is not life-threatening
d) The disease, against which the vaccine protects is common and often severe: often with hospitalization and
the disease is life-threatening
3. VRSE a) Mild side-effects are common and severe side-effects are highly unlikely
b) Mild side-effects rarely occur and severe side-effects are highly unlikely
4. Accessibility a) The vaccine is free of charge and provided by the GP, well baby clinic or occupational physician
b) The vaccine is not reimbursed and is only available with a prescription
5. Local coverage a) 30% of your acquaintances (friends and family) is already vaccinated
b) 60% of your acquaintances (friends and family) is already vaccinated
c) 90% of your acquaintances (friends and family) is already vaccinated
6. Population coverage a) 30% of the Dutch population is already vaccinated
b) 60% of the Dutch population is already vaccinated
c) 90% of the Dutch population is already vaccinated
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score, taken as the mean over the three items, with a
value of ≤2 indicates inadequate health literacy [43–45].
Note that the entire questionnaire was identical for
the ‘oneself’ and ‘child’ group except for the framing of
the subject of interest with respect to the vaccination de-
cision (oneself or one’s child). As indicated, the design
of our Dutch DCE was identical to the design of the
South African DCE [23], which was an improved version
of the design used in Flanders [24]. The design was ex-
plicitly developed to be used for cross-country compari-
sons. The additional background questions of our study
were, however, tailored to the Dutch situation, as was
the addition of health literacy items. Our changes to the
original questionnaires were reviewed and accepted by
the Ethical Committee of the Antwerp University Hos-
pital (UZA, Belgium), granting ethical clearance to per-
form this study (Reference number: 15/2/12).
The relative importance of the attributes and the rela-
tive utility values attached to the attribute levels were
obtained by a Panel Mixed Logit (PML) model using
Hierarchical Bayes estimation. To accommodate for un-
observed preference heterogeneity of the respondents,
we assumed normally distributed preference parameters
without correlation between attributes. We ran 10,000
Bayesian iterations, and used the last 5000 for estima-
tion. The total utility of a vaccination alternative is the
sum of the attributes’ main and interaction effect esti-
mates. Overall significance of the attributes was com-
puted by likelihood ratio (LR) tests and relative
importance of each attribute by the normalized logworth
statistic (−log10 (p-value of the LR-test)). Based on the
finding that both coverage attributes depict a linear
trend, we used linear coding for these attributes. There-
fore, the estimates for these attributes represent the
marginal change in utility when vaccination coverage in-
creases by 10%. The DCE results were analysed using
the Choice Modelling platform of JMP Pro 14 [46].
We estimated the a priori PML model consisting of all
main attribute effects and all two-way interactions be-
tween an attribute and ‘vaccine effectiveness’, ‘VRSE’
and ‘accessibility’, for both the ‘oneself’ and ‘child’ group.
We explored structural differences in observed prefer-
ence heterogeneity among groups of respondents by esti-
mating all two-way interactions between the vaccine
attributes and the background characteristics, attitudes
towards vaccination, risk perception and health literacy
questions in separate models. Next, we studied all indi-
vidually significant two-way interactions in a joint
model, where we iteratively dropped all insignificant co-
variates until we obtained a joint model consisting of
only significant terms. As final step we removed inter-
action terms with a relative importance below a normal-
ized logworth value of 4.
Results
The final dataset consisted of 1547 respondents, divided
into the ‘oneself’ group (n = 825) and the ‘child’ group
(n = 722). The study sample was representative of the
general Dutch population with respect to the back-
ground characteristics gender, age and province. There
was an underrepresentation of individuals with lower
educational attainment. The ‘oneself’ and the ‘child’
groups differed slightly with regard to age and gender
(see Table 1) because assignment to the ‘child’ group
was conditional on being a parent of a child below 18
years, which is closely tied to the age of the parent. With
regard to health literacy, 90.9% of the total sample had a
health literacy mean score above the threshold set by
Chen et al. (> 2), indicating that the vast majority of the
respondents were health literate (Table 1).
With regard to all respondents, both in the ‘oneself’
and the child group, with children below 18 years old
(N = 855), 85.5% report that they fully vaccinated their
child (ren) following the NIP guidelines, 6.5% did not
vaccinate, 5.7% vaccinated their child(ren) partially and
the remaining indicated ‘n/a’ (2.3%). Based on dichoto-
mized 5-point Likert responses on three statements
(‘Vaccinating myself/my child against infectious diseases
is wise’, ‘Vaccinating myself/my child against infectious
disease is important’, ‘Vaccinating myself/my child
against infectious diseases is necessary), at least 80% of
the parents in the ‘child’ group indicated a positive atti-
tude towards vaccination for each statement separately,
whereas this held for 75% in the ‘oneself’ group. Table 3
summarizes the scores on the attitudinal items for the
two groups, where answers were grouped in (completely)
disagree, neutral and (completely) agree, in terms of per-
centages of respondents who agree (in most cases truly
positive) and who provided a neutral score. For both the
‘oneself’ and the ‘child’ group, around 5% were truly
negative about all statements. The respondents in the
‘child’ group were more positive overall regarding the at-
titudinal questions compared to the respondents in the
‘oneself’ group. Strikingly, a large proportion provided a
neutral score on average over all items: 27% in the ‘one-
self’ group and 22.3% in the ‘child’ group. With one
exeption, these background variables did not provide
relevant associations that could explain differences in
decisions made in the DCE. The exception was in case
of the ‘oneself’ group, where the item “If I do not have
myself vaccinated, there is a good chance that I experi-
ence an infectious disease against which vaccination is
done within the NIP” (risk perception), was important
for explaining preference heterogeneity.
‘Oneself’ model
For respondents in the ‘oneself’ group, vaccine effective-
ness was the most important attribute in their vaccine
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decision, followed by burden of disease and accessibility,
which were practically equally important (relative im-
portance of 78 and 76% compared to vaccine effective-
ness – Fig. 1). Far less influential were population
coverage and mild VRSE, with relative importance of 22
and 13%. Local coverage (5%) was ranked last, after
several covariate interactions indicating preference het-
erogeneity. For both population and local coverage,
Table 3 Distribution of answers on attitudinal items by respondent in oneself and child group
Statement Adult Statement Child Answer range % > 3
Oneself
%
neutral
Oneself
% > 3
Child
%
neutral
Child
I find vaccinating myself against infectious
disease
Vaccinating my child following the NIP is Very unwise (1) – very
wise (5)
79.2 14.8 81.9 12.6
I find vaccinating myself against infectious
disease
Vaccinating my child following the NIP is Very unimportant (1) -
very important (5)
78.3 16.4 83.0 12.6
I find vaccinating myself against infectious
disease
Vaccinating my child following the NIP is Very unnecessary (1) -
very necessary (5)
72.5 21.1 81.4 13.0
People who are important to me, find that
I have to vaccinate myself
People who are important to me, think
that I have to vaccinate my child
Totally disagree (1) -
totally agree (5)
46.5 39.3 56.9 33.4
People who are important to me vaccinate
themselves
People who are important to me
vaccinate their child (ren)
Totally disagree (1) -
totally agree (5)
57.3 33.6 71.9 22.2
People who are important to me appreciate
if I vaccinate myself
People who are important to me appreciate
if I vaccinate my child
Totally disagree (1) -
totally agree (5)
51.4 40.1 59.8 33.2
If I do not have myself vaccinated, there is a
good chance that I experience an infectious
disease against which vaccination is done
within the NIP
If I do not have my child vaccinated, there
is a good chance that he / she will develop
an infectious disease against which
vaccination is done within the NIP
Totally disagree (1) -
totally agree (5)
43.4 40.0 56.6 30.6
The NIP is good for the protection of my
own health
The NIP is good for the protection of the
health of my child
Totally disagree (1) -
totally agree (5)
72.0 21.2 79.5 15.0
I find it important that vaccinating myself
contributes to the protection of others
I find it important that vaccinating my child
contributes to the protection of others
Totally disagree (1) -
totally agree (5)
72.8 21.2 75.3 20.1
The infectious diseases against which
vaccination is carried out can be very
severe
The infectious diseases against which
vaccination is carried out can be very severe
Totally disagree (1) -
totally agree (5)
79.5 17.0 82.8 14.4
The adverse side-effects of the vaccinations
within the NIP can be very severe
The adverse side-effects of the vaccinations
within the NIP can be very severe
Totally disagree (1) -
totally agree (5)
26.3 48.2 23.4 43.4
Vaccinating myself is not something I have
to think hard about
Vaccinating my child is not something I
have to think hard about
Totally disagree (1) -
totally agree (5)
72.8 19.2 75.6 15.8
Vaccinating myself is self-evident Vaccinating my child is self-evident Totally disagree (1) -
totally agree (5)
67.0 20.8 75.9 15.5
If I have to decide now, I would vaccinate
myself
If I have to decide now, I would vaccinate
my child following the NIP
Totally disagree (1) -
totally agree (5)
70.4 20.0 79.1 14.0
If I had to make an extra appointment with
my healthcare provider for vaccination, that
would be a reason not to get vaccinated
If I had to make an extra appointment with
my healthcare provider for vaccination, that
would be a reason not to have my child
(ren) vaccinated
Totally disagree (1) -
totally agree (5)
12.4 20.6 18.1 18.1
I trust the information about vaccinations that
I receive from the healthcare provider
I trust the information about vaccinations that I
receive from the healthcare provider
Totally disagree (1) -
totally agree (5)
72.4 20.5 72.8 19.9
I trust the information about vaccinations that
I receive from the government
I trust the information about vaccinations that I
receive from the government
Totally disagree (1) -
totally agree (5)
67.9 22.5 70.4 19.5
It’s everyone’s responsibility to get vaccinated It’s the responsibility of every parent to vaccinate
their child (ren)
Totally disagree (1) -
totally agree (5)
69.2 21.1 69.7 20.8
I find it bad when others do not vaccinate I find it bad when other parents do not vaccinate
their child (ren)
Totally disagree (1) -
totally agree (5)
59.9 27.2 59.8 27.8
Experiencing infectious diseases contributes
to a positive mental and physical
development
Experiencing infectious diseases contributes
to a positive mental and physical
development of my child
Totally disagree (1) -
totally agree (5)
30.1 40.1 33.4 35.2
Experiencing infectious diseases leads to
a better and life-long protection compared
to vaccination
Experiencing infectious diseases leads to
a better and life-long protection compared
to vaccination
Totally disagree (1) -
totally agree (5)
29.8 42.2 34.1 30.7
Wording of statements differs between the ‘oneself’ and ‘child’ groups. Items are scored on a 5-point Likert scale, with specific wording (see Answer
range). Per group the percentages of respondents who provided a score larger than 3 and a neutral score of 3 are given
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respondents preferred a vaccine that has a high uptake
already. In Table 4, the estimates for the ‘oneself’ model
are displayed, representing marginal utilities assigned to
the different attribute levels. Noteworthy is that for bur-
den of disease, the mild levels do not significantly differ (−
0.764 vs. -0.753), indicating no strong preference for one
over the other. For all estimates hold that a more positive
marginal utility translates to a more preferable vaccine pro-
file. As described, burden of disease is expressed in terms of
severity and susceptibility. The estimates show that severity
is assigned more weight, indicating that a vaccine is pre-
ferred against a rare but severe disease over one that pro-
tects against a more frequent but mild disease.
With regard to preference heterogeneity evidenced by
significant covariate interactions (Fig. 2 and Table 4), we
found that respondents with a lower level of education
attached less importance to the disease burden com-
pared to those with a higher educational level. In the
same line, respondents belonging to the target group for
annual influenza vaccination (i.e., being over 60 years of
age and/or having one or more chronic diseases) were
less sensitive towards the disease burden compared to
those who are not eligible. Another significant inter-
action involved the response to the statement ‘The infec-
tious diseases against which vaccination is carried out
can be very severe (risk perception)’ (79.5% of the sub-
sample in the ‘oneself’ group). Respondents who did
agree with this statement had stronger preferences for
accessibility compared to those who did not agree.
‘Child’ model
The best fitting ‘child’ model differed slightly from the
‘oneself’ model. Vaccine effectiveness and burden of dis-
ease were considered equally important in the ‘child’
model (Fig. 1). In addition, accessibility and population
coverage were of lower importance in the ‘child’ model
than in the ‘oneself’ model, but local coverage was of
higher importance. Table 5 presents marginal utility esti-
mates, where, like in the ‘oneself’ model, the least at-
tractive levels of vaccine effectiveness, burden of disease
and accessibility all had a substantial negative effect on
total utility, and vice versa for the most attractive levels.
As in the ‘oneself’ model, the vaccines protecting against
the more severe diseases are preferred over the mild var-
iants. In contrast though, here a vaccine against a fre-
quently occurring mild disease is significantly preferred
over the rare mild variant. A 10% increase in population
coverage led to a marginal utility increase of 0.112, im-
plying that vaccines with a higher global coverage were
preferred. In case of local coverage, the marginal utility
was dependent on accessibility and mild VRSE, due to
significant interaction effects. In both cases, we find a
positive addition to the less preferable levels of VRSE
(more VRSE) and accessibility (need for co-payment)
when local coverage is high.
With regard to preference heterogeneity among the
parents in the ‘child’ group (Fig. 3 and Table 5), we
found significant interactions between burden of disease
and the perceived susceptibility of their child to
Fig. 1 Importance of all statistically significant main and interaction effects (p < 0.05) relative to the most important attribute ‘vaccine
effectiveness’ (‘oneself’ model) and ‘burden of disease’ (‘child’ model)
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Table 4 Panel mixed logit model estimates of the ‘oneself’ model: mean and standard deviation (std dev) and significance of the
attribute effects obtained from likelihood ratio (LR) tests with specified number of degrees of freedom (DF)
Term Mean estimate (std dev; subject std dev) 95% CI Marginal utilitiy LR Chi-square DF P-value
Vaccine effectiveness
50% −0.755 (0.039; 0.323) [−0.833; − 0.682] −0.7551 383.159 1 <.0001
90% 0.755 (0.036; 0.293) [0.685; 0.825] 0.7551
Burden of disease
Rare&mild −0.764 (0.080; 0.225) [− 0.953; − 0.632] −0.7642 308.482 3 <.0001
Common&mild −0.753 (0.079; 0.204) [− 0.900; − 0.595] −0.7533
Rare&severe 0.351 (0.073; 0.144) [0.201; 0.497] 0.3511
Common&severe 1.166 (0.076; 0.180) [1.018; 1.315] 1.1664
Mild VRSE
Common −0.210 (0.027; 0.102) [− 0.264; − 0.159] −0.2103 44.657 1 <.0001
Rare 0.210 (0.025; 0.106) [0.160; 0.260] 0.2103
Accessibility
Co-payment prescription −0.608 (0.041; 0.240) [− 0.691; − 0.533] −0.6085 288.679 1 <.0001
Free accessible 0.608 (0.044; 0.242) [0.522; 0.695] 0.6085
Local coverage (×10%) 0.054 (0.012; 0.122) [0.031; 0.078] 0.0538 15.09 1 0.0001
Global coverage (× 10%) 0.125 (0.013; 0.160) [0.101; 0.153] 0.1247 79.101 1 <.0001
Burden of disease*Educational level
Rare&mild*Low 0.503 (0.134; 0.247) [0.254; 0.789] −0.2617 38.004 6 <.0001
Rare&mild*Mid −0.099 (0.108; 0.283) [− 0.291; 0.169] −0.8635
Rare&mild*High −0.403 (0.082; 0.182) [−0.563; − 0.243] −1.1675
Common&mild*Low 0.196 (0.132; 0.275) [−0.046; 0.451] −0.5572
Common&mild*Mid −0.005 (0.098; 0.246) [−0.195; 0.174] −0.7586
Common&mild*High −0.191 (0.094; 0.242) [−0.375; − 0.006] −0.9441
Rare&severe*Low −0.174 (0.092; 0.180) [−0.365; − 0.014] 0.1774
Rare&severe*Mid 0.182 (0.071; 0.134) [0.053; 0.316] 0.5332
Rare&severe*High −0.008 (0.091; 0.161) [−0.186; 0.170] 0.3427
Common&severe*Low −0.525 (0.094; 0.198) [− 0.708; − 0.341] 0.6415
Common&severe*Mid −0.078 (0.079; 0.167) [−0.232; 0.077] 1.0888
Common&severe*High 0.602 (0.093; 0.200) [0.419; 0.785] 1.7688
Burden of disease*Being target group for influenza vaccination
Rare&mild*Yes 0.216 (0.067; 0.190) [0.093; 0.359] −0.5482 30.472 3 <.0001
Common&mild*Yes 0.179 (0.072; 0.203) [0.034; 0.313] −0.5742
Rare&severe*Yes −0.087 (0.063; 0.133) [−0.217; 0.040] 0.2638
Common&severe*Yes −0.308 (0.063; 0.149) [−0.431; −0.184] 0.8586
Rare&mild*No −0.216 (0.067; 0.145) [−0.348; −0.084] −0.9802
Common&mild*No −0.179 (0.074; 0.187) [−0.323; −0.035] −0.9324
Rare&severe*No 0.087 (0.062; 0.116) [−0.034; 0.209] 0.4384
Common&severe*No 0.308 (0.060; 0.132) [0.191; 0.425] 1.4742
Accessibility*Risk perception Low vs High
Co-payment*Low 0.158 (0.037; 0.256) [0.091; 0.233] −0.4500 18.311 1 <.0001
Co-payment*High −0.158 (0.037; 0.272) [−0.231; −0.085] −0.7669
Free*Low −0.158 (0.043; 0.228) [−0.242; −0.074] 0.4500
Free*High 0.158 (0.037; 0.253) [0.087; 0.230] 0.7669
Note: Mean estimates corresponding to the last level of an attribute were calculated as minus the sum of the estimates for the other levels of
the attribute
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influenza and, additionally, between burden of disease
and using information about vaccination from the inter-
net (other than social media). Respondents who per-
ceived the risk of their child to get influenza in the next
12 months as high were more in favor of a vaccine
against a common and severe disease for their child, but
also more in disfavor of a vaccine against a rare and mild
disease, compared to those who considered their child to
be less vulnerable to influenza. A similar pattern was
found for the interaction with vaccine information from
the internet. Respondents who consulted internet
sources (36.6%) showed a stronger preference for vaccin-
ation against the common and severe level, while being
more negative towards vaccinating against a rare and
mild disease.
Discussion
We identified the most important attributes for vaccin-
ation decision-making among Dutch adults, both for
vaccinating themselves and for vaccinating their child.
We found slight differences between these two perspec-
tives. Although decision-making in both groups was pri-
marily driven by vaccine effectiveness, burden of disease
was more important for those deciding for their child,
compared to those making a decision for themselves.
The attribute burden of disease was expressed both in
terms of disease severity (impact) and susceptibility (dis-
ease frequency). Of these two elements, more weight
was assigned to severity, based on the attribute level util-
ity estimates. Irrespective of perspective, the frequency
of mild VRSE, population coverage and local coverage
among friends and family were relatively unimportant in
the decision. When adults decided for themselves, there
was no significant difference in utility between vaccinat-
ing against a common or rare mild disease. In case of
the decision for their child, a vaccine against a common
and mild disease was preferred over a vaccine that pro-
tects against a mild but rare disease.
We found covariate interactions that differed between
the two groups, whereby being among the target group
for the annual influenza vaccination was the strongest in
the ‘oneself’ model. Understandably, for respondents re-
ceiving this invitation, the question to vaccinate oneself
was possibly related to different experiences compared
to respondents not receiving the invitation, as this group
is more experienced with vaccination overall compared
to adults who do not qualify for influenza vaccination,
and probably only have experience with travel vaccines
for themselves. Following this logic, it is also not unex-
pected that this covariate is not explaining differences
within the ‘child’ model. Notably, this also has to do with
selection effects, because belonging to the risk group,
thus receiving yearly influenza vaccination, is less likely
in the group of parents belonging to the child group.
Contrary to what we expected, we were not able to
find differences in preferences between respondents be-
longing to the orthodox Protestant community and
other respondents. It is possible that those who opt out
of vaccination may have chosen not to cooperate in this
survey in the first place. Furthermore, moderately nega-
tive attitudes among respondents about vaccination in
general (Table 3) may have been suppressed by the
forced choice for either of two “pro-”vaccination options
in the DCE section.
Attitudes towards vaccination are important determi-
nants of vaccine acceptance and vaccine hesitancy [6, 8,
9, 11, 47]. We found a considerable number of neutral
responses on almost all items in the attitudinal question-
naire, ranging from 12.6 to 48.2%. This might indicate
that most participants are passively accepting routinely
offered vaccinations. This could be linked to the highly
reported trust in both information received from
Fig. 2 Marginal utilities for significant covariate interaction terms in the ‘oneself’ model. a Covariate interaction between burden of disease and
educational level. b Covariate interaction between burden of disease and influenza riskgroup. c Covariate interaction between accessibility and
disease risk perception
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Table 5 Panel mixed logit model estimates of the ‘child’ model: mean and standard deviation (std dev) and significance of the
attribute effects obtained from likelihood ratio (LR) tests with specified number of degrees of freedom (DF)
Term Mean estimate (std dev; subject std dev) 95% CI Marginal utility LR Chi-square DF P-value
Vaccine effectiveness
50% −0.970 (0.047; 0.366) [−1.070; −0.888] −0.9701 382.034 1 <.0001
90% 0.970 (0.056; 0.380) [0.861; 1.079] 0.9701
Burden of disease
Rare&mild −1.507 (0.154; 0.377) [−1.811; −1.198] −1.5066 405.516 3 <.0001
Common&mild −0.969 (0.105; 0.311) [−1.179; −0.761] −0.9686
Rare&severe 0.683 (0.099; 0.175) [0.458; 0.842] 0.6831
Common&severe 1.792 (0.108; 0.506) [1.580; 2.004] 1.7921
Mild VRSE
Common −0.518 (0.055; 0.116) [−0.637; −0.417] −0.5175 40.569 1 <.0001
Rare 0.518 (0.071; 0.120) [0.379; 0.656] 0.5175
Accessibility
Co-payment prescription −0.971 (0.059; 0.177) [−1.098; −0.870] −0.9713 154.293 1 <.0001
Free accessible 0.971 (0.092; 0.172) [0.791; 1.152] 0.9713
Local coverage (× 10%) 0.115 (0.016; 0.172) [0.084; 0.146] 0.1147 47.791 1 <.0001
Global coverage (×10%) 0.112 (0.013; 0.141) [0.086; 0.139] 0.1119 49.112 1 <.0001
Mild VRSE*Local coverage
Common*Local coverage 0.041 (0.010; 0.051) [0.024; 0.061] 0.0412 13.527 1 0.0002
Rare*Local coverage −0.041 (0.012; 0.052) [−0.064; −0.018] −0.0412
Accessibility*Local coverage
Co-payment*local 0.044 (0.009; 0.080) [0.028; 0.063] 0.0444 20.147 1 <.0001
Free*local −0.044 (0.014; 0.085) [−0.072; −0.017] −0.0444
Burden of disease*Risk of flu next 12month (Low vs. high)
Rare&mild*High −0.260 (0.112; 0.378) [−0.471; −0.047] −1.7664 19.799 3 0.0002
Common&mild*High −0.155 (0.093; 0.303) [−0.371; 0.007] −1.1238
Rare&severe*High −0.003 (0.086; 0.156) [−0.186; 0.145] 0.6803
Common&severe*High 0.418 (0.094; 0.367) [0.234; 0.602] 2.2098
Rare&mild*Low 0.260 (0.104; 0.489) [0.057; 0.463] −1.2469
Common&mild*Low 0.155 (0.093; 0.245) [−0.028; 0.338] −0.8134
Rare&severe*Low 0.003 (0.098; 0.216) [−0.189; 0.194] 0.6859
Common&severe*Low −0.418 (0.094; 0.601) [−0.602; −0.233] 1.3744
Burden of disease*Information via internet (other than social media)
Rare&mild*No 0.427 (0.099; 0.475) [0.251; 0.625] −1.0800 18.541 3 0.0003
Common&mild*No 0.007 (0.083; 0.256) [−0.143; 0.184] −0.9611
Rare&severe*No −0.048 (0.075; 0.183) [−0.182; 0.113] 0.6346
Common&severe*No −0.386 (0.096; 0.416) [−0.575; −0.196] 1.4066
Rare&mild*Yes −0.427 (0.111; 0.296) [−0.645; −0.208] −1.9332
Common&mild*Yes −0.007 (0.082; 0.189) [−0.167; 0.152] −0.9760
Rare&severe*Yes 0.048 (0.086; 0.204) [−0.120; 0.217] 0.7316
Common&severe*Yes 0.386 (0.094; 0.306) [0.202; 0.569] 2.1777
Note: Mean estimates corresponding to the last level of an attribute were calculated as minus the sum of the estimates for the other levels of the attribute
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healthcare providers and government (> 70%). As de-
scribed, all attitudinal items were used to assess prefer-
ence heterogeneity and all, except for one in the ‘oneself’
model, showed no significant interactions in the joint
models.
Of particular interest is the finding that the marginal
utility estimates of the local (friends and family) and
population coverage attributes were positive. This indi-
cates that a vaccine is more likely to be accepted by an
individual if others accept it too. A possible explanation
is that individuals perceive a high coverage as a social
norm or as public confidence in the vaccination
programme. This link is also reported in Belgium [24],
Australia [18], USA [19] and South Africa [23]. This ob-
servation is contrasting with the rational utility theory,
which argues that when (enough) others are vaccinated
you maximize your own utility by not vaccinating. In-
deed, high coverages protect susceptible individuals via
‘herd protection’, without them being exposed to the
(perceived) side-effects of vaccination [16, 17]. Further-
more, the observation that there is more willingness to
vaccinate when acceptance at local or national level is
high, is important in planning communication strategies
about vaccination programmes. A message that the ac-
ceptance is high among those who have been offered
vaccination recently may lead to a higher uptake among
those who will be offered vaccination. Similarly, a mes-
sage that the current coverage is low may lead to a lower
uptake. Future studies should aim to quantify or further
explain the relationship between reporting vaccination
coverage and willingness to vaccinate. In the ‘child’
group, accessibility and mild VRSE significantly inter-
acted with local coverage, making the effect of social in-
fluence even stronger. Both more common VRSE and
vaccines that require co-payment were valued less nega-
tive if the local coverage was higher.
This study has several limitations. A first limitation is
that although our sample was representative with respect
to gender, age and province, there could be unmeasured
differences between the respondents in our sample and
the general population, for example due to higher com-
puter access in the online panel. Moreover, the sample
population in this study was higher educated compared
to the population’s educational level.
A potential weakness regarding the DCE is the sensi-
tivity to the framing of the VRSE attribute. In the ori-
ginal study in Flanders, this attribute appeared most
important in both the vaccination decision for oneself
and one’s child. In our DCE as well as in the South Afri-
can DCE, this attribute was rephrased. Originally, the
VRSE attribute did not provide any explanation with re-
gard to severity of VRSE. Therefore, its description was
changed such that it explicitly states that VRSE are of
mild nature and rarely result in hospitalization. In our
study, only the frequency of VRSE occurrence was var-
ied. The differences in outcomes between our study and
the South African study on the one hand, and the ori-
ginal Flemish study on the other, highlight the influence
of framing, as well as being as specific as possible with
regard to VRSE.
Fig. 3 Marginal utilities for significant covariate interaction terms in the ‘child’ model. a Covariate interaction between burden of disease and risk
of flu. b Covariate interaction between burden of disease and internet as source of information about vaccination (other than social media)
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Another limitation is that due to the age structure of
respondents with children under the age of 18, which
are mostly between 25 and 40 years old, we observed a
slight underrepresentation of this age group in the ‘one-
self’ group. As a result, we cannot fully explore the dif-
ferences between individuals with and without young
children. However, given that we found only limited dif-
ferences between the two vaccination decision-making
settings and the large sample size, we do not expect that
additional research would lead to different conclusions.
When the findings of this study are compared to both
the Flemish and the South African study we find both
similarities and differences. With regard to ranking of
importance of the attributes the three studies all found
different rank orders. As described, in the Flemish study
VRSE combined with accessibility were the two most
important attributes, followed by effectiveness and bur-
den of disease. In South Africa, vaccine effectiveness was
the most important attribute followed by population
coverage and burden of disease. As in South Africa, here
we found that vaccine effectiveness was the most im-
portant attribute, although in case of the child vaccin-
ation, this was combined with burden of disease. The
importance of vaccine effectiveness was also found in
other DCEs [20, 35, 38]. Per study, the interaction terms
indicating preference heterogeneity differed slightly. In
both this study and the Flemish study it was found that
there was preference heterogeneity related to age and
burden of disease. In the Flemish study it was found that
the older age groups are less sensitive to burden of dis-
ease, i.e. the estimates between the different levels do
not vary much. Here, this was the case with regard to
belonging to the ‘influenza risk group’, which is related
to age. None of the studies found considerable differ-
ences between the decision to vaccinate oneself or one’s
child. Further, for all studies the estimates of the cover-
age attributes were positive, indicating that a higher
coverage was preferred adding to evidence that decisions
of peers are important. With regard to representation of
the study population, all three studies struggled with un-
derrepresentation of the groups with lower educational
attainment.
Conclusions
We performed a discrete choice experiment in The
Netherlands to gain insights into vaccination decision-
making with respect to vaccinating oneself and one’s
child. Vaccine effectiveness, burden of disease and acces-
sibility were the most important attributes in the
decision-making process. Less influential, but still im-
portant contributors to vaccine utility were the popula-
tion and local coverage. For both coverage attributes, we
found positive utility estimates, indicating the effect of
social influence. In the decision to vaccinate one’s child,
estimates were even larger in absolute magnitude due to
interactions with mild VRSE and accessibility, where
higher local coverage increased the utility in magnitude
for the least desirable options (i.e. common VRSE and
co-payment). Our findings indicate that the focus of
communication about vaccination is similar for vaccinat-
ing children and oneself. The message should stress the
effectiveness and low effort of vaccination and clearly ex-
plain the burden of disease against which vaccines pro-
tect. Reporting high uptake rates may help to increase
uptake of vaccination in future vaccination decisions.
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